Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 to 75 years at diagnosis 2. Diagnosis of rectal adenocarcinoma 3. ECOG status: 0～1 4. Clinical stage II (T3-4, N0) or stage III (T1-4, N1-2) 5. Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: 1),Leukocytes ≥ 3.0 x109/ L, 2),Absolute neutrophil count (ANC) ≥ 1.5 x109/ L 3),Platelet count ≥ 100 x109/ L, 4),Hemoglobin (Hb) ≥ 9g/ dL. 5),Total bilirubin ≤1.5 x the upper limit of normal (ULN). 6),Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 x ULN. 7),Serum creatinine ≤ 1.5 x the ULN. 8),Signed informed consent; Exclusion Criteria: 1. Patient had received pelvic radiotherapy; 2. Patient had received systemic chemotherapy 3. Pregnant and Nursing women 4. Had metastatic disease 5. Uncontrolled co-morbid illnesses or other concurrent disease 6. Patient had second malignant disease within 5 years 7. Patients refused to signed informed consent.